Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Heart Failure 2Cardiotoxicity 2Neoplasms 1Lymphoma 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 3Nutrition Assessment 3Exercise 3Carvedilol 3dapagliflozin 2Standard of Care 2Rituximab 2Ivabradine 2Control Groups 2Atorvastatin 2pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Vincristine 1Valsartan 1Trastuzumab 1Surveys and Questionnaires 1Spironolactone 1Sodium Chloride 1Simendan 1Secondary Prevention 1Resistance Training 1Pyruvic Acid 1Prednisolone 1Practice Guidelines as Topic 1Population Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Heart Failure × Ivabradine × Clear all
NCT04030546 2019-12-18

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Vilnius University

Phase 3 Unknown
128 enrolled

Heart Failure, Cardiotoxicity

NCT03650205 2019-04-02

IPAC

University of Sao Paulo

Phase NA Unknown
160 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡